STOCK TITAN

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rhea-AI Summary

Iovance Biotherapeutics (Nasdaq: IOVA) approved inducement stock options covering 175,840 common shares for new employees on November 19, 2026. The grants went to 22 new, non-executive employees under the Amended and Restated 2021 Inducement Plan. The $7.31 exercise price matched the stock’s closing price on the grant date.

The options vest over three years. One-third vests on the first anniversary of each employee’s start date, and the rest vests in eight quarterly installments over the next two years, subject to continued employment through each vesting date.

Loading...
Loading translation...

Positive

  • None.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.Options on 175,840 common shares could dilute existing shareholders if exercised at $7.31 per share

Key Figures

Options granted: 175,840 shares Recipients: 22 employees Exercise price: $7.31 +2 more
Options granted
175,840 shares
Inducement stock options for new non-executive employees
Recipients
22 employees
New, non-executive employees
Exercise price
$7.31
Per option
Vesting period
Three years
Subject to continued employment through applicable vesting dates
Vesting schedule
One-third on the first anniversary; remaining shares in eight quarterly installments
Installments commence in the first quarter following the First Vesting Date

Key Terms

tumor infiltrating lymphocyte, nasdaq listing rule 5635(c)(4)
2 terms
tumor infiltrating lymphocyte medical
"novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies"
Tumor-infiltrating lymphocyte (TIL) is an immune cell found inside a tumor that can recognize and attack cancer cells; researchers can extract and multiply these patient-derived cells to use as a personalized therapy. Investors watch TILs because therapies built from them offer a targeted, individualized approach—like retraining a patient’s own soldiers to fight a specific enemy—which can influence clinical trial outcomes, regulatory decisions, and the commercial value of biotech companies.
nasdaq listing rule 5635(c)(4) regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

PHILADELPHIA, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on November 19, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 175,840 shares of Iovance’s common stock to twenty-two new, non-executive employees.

The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of $7.31, the closing price of Iovance’s common stock on the Date of Grant. Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date (the “First Vesting Date”) and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit www.iovance.com.

Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

CONTACTS

Investors
IR@iovance.com
650-260-7120 ext. 150

Media
PR@iovance.com
650-260-7120 ext. 150


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares do Iovance Biotherapeutics’ November 19, 2026 inducement options cover, and what is the exercise price?

Iovance granted options covering 175,840 common shares at a $7.31 exercise price to 22 new, non-executive employees.

When do Iovance Biotherapeutics’ November 19, 2026 inducement options vest?

The options vest over three years, starting with one-third on the first anniversary of each employee’s start date. The remainder vests in eight quarterly installments over the next two years, provided the employee remains with Iovance through each applicable vesting date.

Keep reading